[Helicobacter pylori eradication. Triple or quadruple therapy?, Long or short treatment?].
Calvet
X
X
Unitat de Malalties Digestives. Hospital de Sabadell-Institut Universitari Parc Taulí (UAB). Sabadell. Barcelona. España. xcalvet@cspt.es
Gené
E
E
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004351:Drug Resistance; D024901:Drug Resistance, Multiple, Bacterial; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D009942:Organometallic Compounds / Q000627:therapeutic use; D054328:Proton Pump Inhibitors; D011899:Ranitidine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004791:Enzyme Inhibitors; D006635:Histamine H2 Antagonists; D009942:Organometallic Compounds; D054328:Proton Pump Inhibitors; D011899:Ranitidine; C002791:bismuth tripotassium dicitrate